UV Flu Technologies Inc. Announces Appointment of Glenn Bushee to Board of Directors

May 26, 2010 |

4 min read

CENTERVILLE, MA--(Marketwire - May 26, 2010) - UV Flu Technologies, Inc. (OTCBB: UVFT) (“UV Flu” or the “Company”) is pleased to announce the appointment of Mr. Glen Bushee and welcomes him to his role as the newest member of the Company’s Board of Directors.

Mr. Bushee currently serves as the President of Brite-Strike Tactical Illumination Products. For the past 20 years Mr. Bushee has held Senior Management positions for a number of organizations including Brite-Strike, 3P North America, and Sunbeam Corp. As part of his responsibilities, he was closely involved in the ongoing product design process including extended feature developments based on marketplace demands. For a number of years, he lived in China in order to closely oversee all facets of production from design to price point. The years spent in China provide Mr. Bushee with an extensive network of industry contacts and familiarity with several manufacturing concerns of significant interest to UV Flu.

Jack Lennon, President of UV Flu Technologies, states, “Glenn brings over 30 years’ experience in sales and marketing and an intimate understanding of how to successfully manufacture in China. While he was President of 3P North America, he also designed and sold a line of UV air purifiers called Comfort Mist, which sold almost $20 million of product annually. His successes and combination of technical, managerial and marketing knowledge is a huge plus for our Company at this important stage of our growth.”

In related news, the company anticipates commercial availability of the recently updated ViraTech UV-400 shortly. Those interested in the product, or wishing to pre-order are invited to contact the distributor, Puravair LLC at 1-866-6-PURAVAIR or by email at info@puravair.com.

Further details regarding the Company’s business, financial reports, appointments and agreements are filed as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.

About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality (“IAQ”) industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis. The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com. For sales: www.puravair.com.

Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

ON BEHALF OF THE BOARD

UV Flu Technologies, Inc.
-----------------------------
John J. Lennon, President & CEO